- Active, not recruiting
NCT02963493: Phase 2 - Melphalan Flufenamide (Melflufen) With Dexamethasone in Relapsed MM (HORIZON)
Updated: Jun 21, 2022
HORIZON
A Study of Melphalan Flufenamide (Melflufen) in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients (HORIZON)
This study will evaluate melflufen in combination with dexamethasone in the treatment of relapsed refractory multiple myeloma in adult patients with disease refractory to pomalidomide and/or an anti-CD38 monoclonal antibody. All patients in the study will be treated with melflufen on Day 1 and dexamethasone on Days 1, 8, 15 and 22 of each 28-day cycle.
Sponsor
Oncopeptides AB
Collaborator
Precision For Medicine
Multiple locations
International Study
ClinicalTrials.gov Identifier: NCT02963493
Official Title: A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
First Posted : November 15, 2016
Click here to see details on ClinicalTrials.gov
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
PMID: 33296242; J Clin Oncol; March 2021
Click here to see details
* Dexamethasone (Decadron)
* Melphalan Flufenamide (Melflufen) Pepaxto
- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston
- New York: Memorial Sloan-Kettering Cancer Center New York
- Texas: Baylor University Medical Center Dallas
Locations
United States, California
United States, Florida
United States, Illinois
United States, Massachusetts
United States, Michigan
United States, New York
United States, Pennsylvania
United States, Texas
Europe
France
Italy
Spain